Further Winrevair PAH results revealed at ACC

Merck & Co (NYSE: MRK) has announced the first presentation of full results from the Phase III ZENITH trial of Winrevair (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension World Health Organization functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. 

At a median follow-up of 10.6 months, Winrevair reduced the relative risk of major morbidity and mortality events - the composite of all-cause death, lung transplantation and PAH worsening-related hospitalization of at least 24 hours - by 76% compared to placebo. 

For patients treated with Winrevair, 17.4% experienced one or more major morbidity and mortality events, compared with 54.7% of those in the placebo arm.